← Back to screener

Zenas BioPharma, Inc. ZBIO

Rank #2041 · Nasdaq · $1.8B market cap
⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.
Score
35.6
P/E
-11.4
P/B
-7.94
ROE
69.5%
Op. Margin
-3277.8%
Debt Ratio
-25%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -11.4x, P/B -7.94x. Ranks in the top 92% of the universe.

Profitability ★★☆☆☆
Average

ROE 69.5%. Ranks in the top 52% of the universe.

Safety ★★★★★
Excellent

Debt ratio -25%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 90.0% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024$0.1B$-0.0B$-0.0B$-0.2B-74.3-23
2025$0.0B$-0.2B$-0.2B$-0.2B-3277.8-25

← See the full screener